154 related articles for article (PubMed ID: 17118654)
1. Spirodiketopiperazine-based CCR5 antagonists: Lead optimization from biologically active metabolite.
Nishizawa R; Nishiyama T; Hisaichi K; Matsunaga N; Minamoto C; Habashita H; Takaoka Y; Toda M; Shibayama S; Tada H; Sagawa K; Fukushima D; Maeda K; Mitsuya H
Bioorg Med Chem Lett; 2007 Feb; 17(3):727-31. PubMed ID: 17118654
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological evaluation of the combinatorial library with a new spirodiketopiperazine scaffold. Discovery of novel potent and selective low-molecular-weight CCR5 antagonists.
Habashita H; Kokubo M; Hamano S; Hamanaka N; Toda M; Shibayama S; Tada H; Sagawa K; Fukushima D; Maeda K; Mitsuya H
J Med Chem; 2006 Jul; 49(14):4140-52. PubMed ID: 16821774
[TBL] [Abstract][Full Text] [Related]
3. TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans.
Baba M; Takashima K; Miyake H; Kanzaki N; Teshima K; Wang X; Shiraishi M; Iizawa Y
Antimicrob Agents Chemother; 2005 Nov; 49(11):4584-91. PubMed ID: 16251299
[TBL] [Abstract][Full Text] [Related]
4. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro.
Maeda K; Nakata H; Koh Y; Miyakawa T; Ogata H; Takaoka Y; Shibayama S; Sagawa K; Fukushima D; Moravek J; Koyanagi Y; Mitsuya H
J Virol; 2004 Aug; 78(16):8654-62. PubMed ID: 15280474
[TBL] [Abstract][Full Text] [Related]
5. [2-(4-Phenyl-4-piperidinyl)ethyl]amine based CCR5 antagonists: derivatizations at the N-terminal of the piperidine ring.
Duan M; Aquino C; Ferris R; Kazmierski WM; Kenakin T; Koble C; Wheelan P; Watson C; Youngman M
Bioorg Med Chem Lett; 2009 Mar; 19(6):1610-3. PubMed ID: 19233649
[TBL] [Abstract][Full Text] [Related]
6. Orally active CCR5 antagonists as anti-HIV-1 agents. Part 3: Synthesis and biological activities of 1-benzazepine derivatives containing a sulfoxide moiety.
Seto M; Miyamoto N; Aikawa K; Aramaki Y; Kanzaki N; Iizawa Y; Baba M; Shiraishi M
Bioorg Med Chem; 2005 Jan; 13(2):363-86. PubMed ID: 15598559
[TBL] [Abstract][Full Text] [Related]
7. CCR5 antagonists as anti-HIV-1 agents. Part 3: Synthesis and biological evaluation of piperidine-4-carboxamide derivatives.
Imamura S; Nishikawa Y; Ichikawa T; Hattori T; Matsushita Y; Hashiguchi S; Kanzaki N; Iizawa Y; Baba M; Sugihara Y
Bioorg Med Chem; 2005 Jan; 13(2):397-416. PubMed ID: 15598561
[TBL] [Abstract][Full Text] [Related]
8. Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5.
Maeda K; Yoshimura K; Shibayama S; Habashita H; Tada H; Sagawa K; Miyakawa T; Aoki M; Fukushima D; Mitsuya H
J Biol Chem; 2001 Sep; 276(37):35194-200. PubMed ID: 11454872
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the human chemokine receptor CCR5 by variecolin and variecolol and isolation of four new variecolin analogues, emericolins A-D, from Emericella aurantiobrunnea.
Yoganathan K; Rossant C; Glover RP; Cao S; Vittal JJ; Ng S; Huang Y; Buss AD; Butler MS
J Nat Prod; 2004 Oct; 67(10):1681-4. PubMed ID: 15497939
[TBL] [Abstract][Full Text] [Related]
10. CCR5 antagonists as anti-HIV-1 agents. Part 2: Synthesis and biological evaluation of N-[3-(4-benzylpiperidin-1-yl)propyl]-N,N'-diphenylureas.
Imamura S; Kurasawa O; Nara Y; Ichikawa T; Nishikawa Y; Iida T; Hashiguchi S; Kanzaki N; Iizawa Y; Baba M; Sugihara Y
Bioorg Med Chem; 2004 May; 12(9):2295-306. PubMed ID: 15080927
[TBL] [Abstract][Full Text] [Related]
11. 10-Methoxydihydrofuscin, fuscinarin, and fuscin, novel antagonists of the human CCR5 receptor from Oidiodendron griseum.
Yoganathan K; Rossant C; Ng S; Huang Y; Butler MS; Buss AD
J Nat Prod; 2003 Aug; 66(8):1116-7. PubMed ID: 12932138
[TBL] [Abstract][Full Text] [Related]
12. Antagonists of the human CCR5 receptor as anti-HIV-1 agents. part 1: discovery and initial structure-activity relationships for 1 -amino-2-phenyl-4-(piperidin-1-yl)butanes.
Dorn CP; Finke PE; Oates B; Budhu RJ; Mills SG; MacCoss M; Malkowitz L; Springer MS; Daugherty BL; Gould SL; DeMartino JA; Siciliano SJ; Carella A; Carver G; Holmes K; Danzeisen R; Hazuda D; Kessler J; Lineberger J; Miller M; Schleif WA; Emini EA
Bioorg Med Chem Lett; 2001 Jan; 11(2):259-64. PubMed ID: 11206473
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel (S)-alpha-phenyl-gamma-amino butanamide containing CCR5 antagonists via functionality inversion approach.
Zhang HS; Feng DZ; Chen L; Long YQ
Bioorg Med Chem Lett; 2010 Apr; 20(7):2219-23. PubMed ID: 20207141
[TBL] [Abstract][Full Text] [Related]
14. Studies on the structure-activity relationship of 1,3,3,4-tetra-substituted pyrrolidine embodied CCR5 receptor antagonists. Part 2: Discovery of highly potent anti-HIV agents.
Li B; Jones ED; Zhou E; Chen L; Baylis DC; Yu S; Wang M; He X; Coates JA; Rhodes DI; Pei G; Deadman JJ; Xie X; Ma D
Bioorg Med Chem Lett; 2010 Sep; 20(17):5334-6. PubMed ID: 20674358
[TBL] [Abstract][Full Text] [Related]
15. Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure-activity relationships for substituted 2-Aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanes.
Finke PE; Meurer LC; Oates B; Mills SG; MacCoss M; Malkowitz L; Springer MS; Daugherty BL; Gould SL; DeMartino JA; Siciliano SJ; Carella A; Carver G; Holmes K; Danzeisen R; Hazuda D; Kessler J; Lineberger J; Miller M; Schleif WA; Emini EA
Bioorg Med Chem Lett; 2001 Jan; 11(2):265-70. PubMed ID: 11206474
[TBL] [Abstract][Full Text] [Related]
16. Identification of peptide ligands to the chemokine receptor CCR5 and their maturation by gene shuffling.
Vyroubalova EC; Hartley O; Mermod N; Fisch I
Mol Immunol; 2006 Apr; 43(10):1573-8. PubMed ID: 16280164
[TBL] [Abstract][Full Text] [Related]
17. Syntheses and SAR studies of 4-(heteroarylpiperdin-1-yl-methyl)-pyrrolidin-1-yl-acetic acid antagonists of the human CCR5 chemokine receptor.
Shankaran K; Donnelly KL; Shah SK; Guthikonda RN; MacCoss M; Mills SG; Gould SL; Malkowitz L; Siciliano SJ; Springer MS; Carella A; Carver G; Hazuda D; Holmes K; Kessler J; Lineberger J; Miller MD; Emini EA; Schleif WA
Bioorg Med Chem Lett; 2004 Jul; 14(13):3419-24. PubMed ID: 15177445
[TBL] [Abstract][Full Text] [Related]
18. Analysis of second messenger pathways stimulated by different chemokines acting at the chemokine receptor CCR5.
Leach K; Charlton SJ; Strange PG
Biochem Pharmacol; 2007 Sep; 74(6):881-90. PubMed ID: 17645873
[TBL] [Abstract][Full Text] [Related]
19. 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 3: polar functionality and its effect on anti-HIV-1 activity.
Hale JJ; Budhu RJ; Mills SG; MacCoss M; Gould SL; DeMartino JA; Springer MS; Siciliano SJ; Malkowitz L; Schleif WA; Hazuda D; Miller M; Kessler J; Danzeisen R; Holmes K; Lineberger J; Carella A; Carver G; Emini EA
Bioorg Med Chem Lett; 2002 Oct; 12(20):2997-3000. PubMed ID: 12270192
[TBL] [Abstract][Full Text] [Related]
20. Syntheses and biological evaluation of 5-(piperidin-1-yl)-3-phenyl-pentylsulfones as CCR5 antagonists.
Shankaran K; Donnelly KL; Shah SK; Caldwell CG; Chen P; Finke PE; Oates B; MacCoss M; Mills SG; DeMartino JA; Gould SL; Malkowitz L; Siciliano SJ; Springer MS; Kwei G; Carella A; Carver G; Danzeisen R; Hazuda D; Holmes K; Kessler J; Lineberger J; Miller MD; Emini EA; Schleif WA
Bioorg Med Chem Lett; 2004 Jul; 14(13):3589-93. PubMed ID: 15177481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
